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CalG3 Calicheamicinone-4,6-dideoxy-4-hydroxylamino- -D-glucosyltransferase from
Micromonospora echinospora
CAZy Carbohydrate-Active enZymes database
CN-I Crigler-Najjar syndrome type I
CN-II Crigler-Najjar syndrome type II





GmIF7GT UDP-isoflavone 7-O-glucosyltransferase from the roots of soybean (Glycine
max) seedlings
GT Glycosyltransferase
GtfB TDP/UDP-glucose:aglycosyl-vancomycin glucosyltransferase from
Amycolatopsis orientalis A82846
GtfA dTDP- -L-4-epi-epivancosamine: epivancosaminyltransferase from
Amycolatopsis orientalis A82846
GtfD UDP- -L-4-epi-vancosamine: vancomycin-pseudoaglycone
vancosaminyltransferase from Amycolatopsis orientalis ATCC19795
HA Hemagglutinin
HEK293 Human embryonic kidney cells line 293
HPLC High performance liquid chromatography
IMAC Immobilised metal ion affinity chromatography
Km Michaelis constant
MBP Maltose binding protein
4-MU 4-methylumbelliferone
MurG UDP-GlcNAc: N-acetylmuramyl-(pentapeptide)-PP-C55
N-acetylglucosaminyltransferase from Eschericia coli
NDP Nucleotide diphosphate
OleD Oleandomycin glycosyltransferase D
OleI Oleandomycin glycosyltransferase I
RMSD Root mean square deviation
Sf9 Spodoptera frugiperda-derived cell line
SN-38 7-Ethyl-10-hydroxycamptothecin
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
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UDPGA Uridine diphosphoglucuronic acid
UGT UDP-glucuronosyltransferase
UGT71G1  Triterpene/flavonoid glycosyltransferase from the legume Medicago truncatula
UrdGT2 C-C bond-forming dTDP-D-olivose-transferase from Streptomyces fradiae
UGT85H2 Multifunctional UDP-glucose : (iso)flavonoid -glucosyltransferase from
Medicago truncatula
UGT72B1 2,5-dihydroxybenzoic acid-3,4-dihydroxybenzoic acid-glucosyltransferase from
Arabidopsis thaliana
UPLC Ultra performance liquid chromatography
VvGT1 UPD-glucose: flavonoid 3-O-glucosyltransferase from red grape (Vitis vinifera)
Vmax Maximum velocity
1YD Y486D mutant form of UGT1A1
6YD Y485D mutant form of UGT1A6
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UDP-glucuronosyltransferases (UGTs, EC 2.4.1.17) are membrane bound
glycosyltransferases located in the endoplasmic reticulum (ER). They catalyse the transfer of
glucuronic acid from UDP-glucuronic acid (UDPGA) to endogenic or exogenic compounds,
usually highly lipophilic molecules. As a consequence the aqueous solubility of the substrate
(aglycone) is increased and it is more easily excreted from the body. UGTs consist of two
domains located on the lumenal side of the ER membrane, a single-pass transmembrane
helix and a short cytosolic tail. Currently, 19 different UGTs are known in man and, based
on sequence and gene organisation, they are divided into three subfamilies: UGT1A,
UGT2A,  and  UGT2B.  The  functional  unit  of  UGTs  probably  consists  of  two  or  more
monomers.
Bilirubin, a degradation product of haemoglobin, is glucuronidated by UGT1A1 and
depressed activity of this enzyme can lead to hyperbilirubinemia. The UGT1A1 Y486D
mutation causes hyperbilirubinemia and, due to exon sharing in the UGT1A subfamily,
individuals that are homozygous for the 1A1-Y486D mutation carry the corresponding
mutation in all their UGT1As. Recombinant UGT1A6 carrying this mutation, 6YD, had
drastically decreased glucuronidation activity and increased Km for both the aglycone and
UDPGA. However, co-infection of the 6YD mutant with UGT1A4 partially restored the
glucuronidation activity and decreased the Kms of substrates to close to wild-type levels.
Strong evidence for the formation of a tight hetero-oligomer was provided by the co-
purification experiment.
The purification of UGTs in an active form has turned out to be difficult and tortuous, as
is their expression in the quantities required for crystallisation purposes. In the absence of a
three-dimensional structure of the full-length enzyme, I used other methods to obtain
structural information. Binding of the co-substrate UDPGA was studied in UGT1A6,
UGT1A9, UGT1A10 and UGT2B7 by site-directed mutagenesis, modelling, single-point
activity and kinetic measurements with several substrates. The results indicated that residues
H371, E379, D395 and Q396 (UGT1A6 numbering) are involved in UDPGA binding. The
effects of the mutations on the glucuronidation rate were substrate- and isoform-dependent.
UGTs  belong  to  the  GT1  family  of  glycosyltransferases.  Many  enzymes  in  this  family
use a serine protease-type catalytic mechanism, where histidine and aspartate form a
“catalytic dyad”. Such a pair in human UGT1A9 could be H37 and either D143 or D148.
This histidine is not totally conserved among human UGTs, being replaced by proline in
UGT1A4 and leucine in UGT2B10. Interestingly, while most human UGTs tend to
glucuronidate phenolic compounds leading to the formation of O-glucuronides, both
UGT1A4 and UGT2B10 are more specialised for N-glucuronidation. The roles of H37, D143
and D148 were investigated in UGT1A9 by site-directed mutagenesis, single-point activity
and kinetic measurements. H37 was shown to be much more important in O- than in N-
glucuronidation. D148 also played a different role in these two types of glucuronidation
reactions. The results implied that H37-D143 is the catalytic dyad in UGT1A9, but could not




Mammalian UDP-glucuronosyltransferases (UGTs) play a major role in converting both
exogenic and endogenic substances to more water soluble forms by conjugating them with
the glucuronic acid from UDP-glucuronic acid (UDPGA). This enzymatic reaction is a
biotransformation reaction, the purpose of which in general is to remove foreign lipophilic
compounds from the body to bile or urine. These elimination processes are divided into
phase I and phase II metabolism. Cytochrome P450 mono-oxygenases (CYPs) are the major
phase  I  enzymes  and  UDP-glucuronosyltransferases  are  the  major  phase  II  enzymes.  Quite
often, the molecules undergo modifications in both phases before they can be excreted
(Ioannides, 2002).
The type of enzymatic reaction catalysed by UGTs, conjugation of a carbohydrate group
to  another  molecule,  is  one  of  the  most  common  reactions  in  nature  and  the  enzymes
catalysing these reactions are called glycosyltransferases (GTs) (Davies, et al., 2005). UGTs
belong to this enzyme class and, based on sequence and predicted structure, they are further
classified as members of the GT-B family and the GT1 subfamily. Unlike most other GT1
enzymes,  which  are  soluble  (Ross, et al., 2001) and function as monomers (Finel and
Kurkela, 2008), mammalian UGTs are  bound to the endoplasmic reticulum (ER) and most
probably function as dimers or higher oligomers (Finel and Kurkela, 2008; Coleman, et al.,
1997). One purpose of the studies in the present thesis was to shed light on the homo- or
hetero-oligomerisation of UGTs and its possible physiological significance (Study I).
Due  to  the  nature  of  the  reaction,  UGTs  have  a  wide  variety  of  different  kinds  of
substrates that prior to glucuronidation, are referred to as aglycones. Each of the currently
known 19 human UGT-isoforms glucuronidates several substrates; in addition one substrate
is usually glucuronidated by several isoforms. This kind of promiscuity is advantageous for
enzymes involved in detoxification, but understanding the mechanism behind it is still one of
the major challenges in the UGT research field. Since 1953, when UDPGA was first
characterised as a donor nucleotide sugar in glucuronidation reactions (Dutton and Storey,
1953), our knowledge of these enzymes and reactions has increased considerably. However,
due to the inherent difficulties of expressing and purifying these membrane-bound enzymes
as active proteins, no complete three-dimensional structures of any of the isoforms have yet
been determined. Only after solving some eukaryotic GT1 structures during the last few
years (Shao, et al., 2005; Offen, et al., 2006; Brazier-Hicks, et al., 2007; Li, et al., 2007b)
and obtaining a partial crystal structure of the carboxy-terminal domain of human UGT2B7
(Miley, et al., 2007), have we managed to gain some insight into the possible structural
details of human UGTs. In the present thesis I used homology modelling, site-directed
mutagenesis,  single  point  activity  and  kinetic  measurements  (Studies  II,  III  and  IV)  to
identify which residues are involved in UDPGA and aglycone binding and to examine the
catalytic mechanism.
The most common type of glucuronidation reaction is O-glucuronidation, where the
glucuronic acid is conjugated to a hydroxyl group of the aglycone, but amino groups can also
serve as conjugation targets leading to the formation of N-glucuronides. Certain UGT
isoforms, namely UGT1A4 and UGT2B10, seem to be more specialised in less studied N-
glucronidation (Green, et al., 1995; Green, et al., 1998; Green and Tephly, 1998; Kaivosaari,
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et al., 2002; Sorich, et al., 2006; Chen, et al., 2007; Kaivosaari, et al., 2007). The
mechanistic differences between O- and N-glucuronidation are presented and discussed in
the present thesis (Study IV).
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2. Review of the literature
2.1. Xenobiotic metabolism
It has been estimated that during one day humans consume 5,000 – 10,000 different
chemicals, of which quite a few are potential carcinogens. Most of these chemicals come
from our diet and are natural substances originating from plants or generated during cooking
(Ames and Gold, 1998; Ames, et al., 1990). They do not naturally occur in our bodies and
we cannot utilise them; thus they are recognised as foreign compounds that should be
eliminated, and are frequently called xenobiotics (Greek: xenos = “foreign”, bios = ”life”).
However,  the  chemicals  that  finally  reach  our  bodies  are  usually  lipophilic  and  cannot  be
excreted via bile or urine without modification. For this purpose, the body has efficient
enzyme systems to convert these hydrophobic substances into more hydrophilic ones and
thus facilitate their elimination. This xenobiotic biotransformation process protects us from
hazardous effects in several ways: it shortens our exposure to the foreign chemicals and
prevents their accumulation in our bodies. Usually, the biological activity of the compound is
abolished during this biotransformation process, but in some cases the chemical metabolite
may be more toxic than the parent compound (toxification or bioactivation). The cellular
localisation of the phase I and phase II biotransformation enzymes is mainly the endoplasmic
reticulum (ER) and cytosol. They are found in many different tissues, but the liver is the
main site for xenobiotic metabolism (Ioannides, 2002).
2.1.1. Phase I metabolism
Three types of Phase I metabolism exist: oxidation, reduction and hydrolysis. The oxidation
reactions are catalysed by different enzymes, such as cytochrome P450 (CYP), flavin mono-
oxygenases (FMO) and amine, xanthine and aldehyde oxidases (Ioannides, 2002; Zhang, et
al., 2006). Of these, the cytochrome P450 enzymes form the most important group. They
catalyse  reactions,  in  which  one  atom  of  oxygen  is  incorporated  into  the  organic  substrate
and the other oxygen atom is reduced to water. The aromatic and aliphatic hydroxylation
reactions  are  common  examples  of  such  oxidation  reactions  (Guengerich,  2002;  Sheweita,
2000). It is estimated that CYP superfamily enzymes are involved in the metabolism of about
80% of current drugs (Fisher, et al., 2001). The other possible phase I reactions are
epoxidation, dealkylation, oxidative deamination, nitroreduction, azoreduction, reductive
dehalogenation and hydrolysis reactions. Thus, in phase I reactions some functional group
(e.g.  –OH, -COOH, -NH2 or -SH) is typically introduced (Zhang, et al., 2006). Often these
reactions are followed by phase II reactions (Fig. 2.1).
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2.1.2. Phase II metabolism
Phase II metabolic reactions are conjugation reactions primarily catalysed by different kinds
of transferases. In these reactions a molecule is added to a functional group, often that which
was added during phase I. Phase II conjugation reactions include sulfonation catalysed by
cytosolic sulfotransferases, gluthatione conjugation by glutathione S-transferases,
methylation by methyltransferases, acetylation by acetyltransferases and amino acid
conjugation by amino acid acyltransferases. However, the most important phase II reaction is
glucuronidation catalysed by UDP-glucuronosyltransferases. They are responsible for about
35% of all drugs metabolised by phase II enzymes (Kiang, et al., 2005).  I discuss UGTs and
their relationship to other enzymes in what follows.
Figure 2.1 Schematic representation of phase I and phase II metabolic reactions. Molecules can
undergo both phase I and phase II reactions or only one of the two. In the figure, oxygen (O) can be
also replaced by nitrogen (N) or sulfur (S).
2.2. Glycosyltransferases
Based on amino acid sequence and predicted structure, human UDP-
glucuronosyltransferases belong to the glycosyltransferase (GT) superfamily, which forms
one of the largest enzyme groups in nature. They catalyse the transfer of a glycosyl moiety
from a sugar donor to a saccharide, protein, lipid, DNA or small molecule acceptor (Unligil
and Rini, 2000) and are thus involved in the synthesis of oligosaccharides, polysaccharides,
and glycoconjugates (Breton, et al., 2006). Like human UGTs, the majority of GTs use an
activated nucleotide sugar as donor. Glycosyltransferases have a significant role in many
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important biological processes, like recognition and signalling (Breton and Imberty, 1999;
Campbell, et al., 1997). Based on sequences and donor sugars, glycosyltransferases have
been classified into different families (91 at the moment). The most recent information and
classification of these enzymes is available from the continuously updated carbohydrate-
active enzyme database (CAZy) at http://afmb.cnrs-mrs.fr/CAZY/ (Campbell, et al., 1997;
Coutinho, et al., 2003).
Even  though  the  diversity  of  the  reactions  catalysed  and  the  amino  acid  sequences  is
high, almost all the glycosyltransferases so far have been found to adopt either the GT-A or
GT-B folds (Unligil and Rini, 2000; Bourne and Henrissat, 2001; Hu and Walker, 2002;
Lairson, et al., 2008). The GT-A fold consists of two dissimilar  domains, with the
amino-terminal domain binding the nucleotide sugar and the highly variable carboxy-
terminal domain binding the acceptor. Almost all the GT-A family members have a common
DxD motif, which is involved in coordinating a divalent cation, usually a manganese or
magnesium ion, in the catalytic centre. The metal ion is required for the binding of the
nucleotide sugar (Breton and Imberty, 1999; Wiggins and Munro, 1998). The GT-A fold was
originally detected in the nucleotide-diphospho-sugar transferase SpsA from Bacillus subtilis
(Charnock and Davies, 1999) (Fig. 2.2A).
Figure 2.2 Cartoon representation of glycosyltransferase GT-A and GT-B folds. Beta sheets are
coloured blue, alpha helices purple, nucleotide sugar yellow and magnesium ions in the GT-A fold
red. A. Nucleotide-diphospho-sugar transferase SpsA from Bacillus subtilis. B. T4 phage -
glucosyltransferase.
The GT-B fold consists of two rather similar Rossman fold domains separated by a linker
region, with the catalytic site placed between the two domains (Fig. 2.2B). The amino-
terminal domain binds the acceptor and the carboxy-terminal domain the nucleotide-sugar
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(Breton, et al., 2006; Bourne and Henrissat, 2001). Even though the carboxy-terminal
domains between different GT-B family members are highly conserved, no strictly
conserved residues have been found (Hu and Walker, 2002). In contrast to the GT-A family,
there is no evidence of a bound metal ion, although divalent cations may be needed for full
activity. The first GT-B structure solved was phage T4 -glucosyltransferase (Vrielink, et al.,
1994) (Fig. 2.2B).
GT1 enzymes
Within the superfamily of glycosyltransferases, human UGTs belong to the GT1 family
according to CAZy database. Enzymes of that family adopt the GT-B fold and typically
transfer sugars to lipophilic small-molecule acceptors (Bowles, et al., 2006). About 50% of
the GT1 family enzymes contain a signature motif (Bowles, et al., 2006; Mackenzie, et al.,
1997; Paquette, et al., 2003) (see Fig. 2.6). So far, the GT1 family contains seven full three-
dimensional structures from bacteria and four from plants. Bacterial TDP-epi-
vancosaminyltransferase GtfA, UDP-glucosyltransferase GtfB and vancosaminyltransferase
GtfD are involved in vancomycin synthesis (Mulichak, et al., 2003; Mulichak, et al., 2001;
Mulichak, et al., 2004); oleandomycin glycosyltransferases OleD and OleI inactivate
oleandomycin and diverse macrolide antibiotics (Bolam, et al., 2007); CalG3 is
calicheamicinone 4,6-dideoxy-4-hydroxylamino- -D-glucosyltransferase (Zhang, et al.,
2008);   and  glycosyltransferase  UrdGT2 catalyses  the  formation  of  a  C-C bond between a
polyketide aglycone and D-olivose (Mittler, et al., 2007). Three of the plant GT1 structures,
UGT71G1, VvGT1 and UGT85H2 are flavonoid glucosyltransferases (Shao, et al., 2005;
Offen, et al., 2006; Li, et al., 2007b) and UGT72B1 is a bifunctional N- and O-
glucosyltransferase (Brazier-Hicks, et al., 2007). In addition there are two partial structures:
the carboxy-terminal domains of human UGT2B7 (Miley, et al., 2007) and yeast N-
acetylglucosamine transferase (ALG13) (Wang, et al., 2008). Although the sequence identity
between human UGTs and those GT1 enzymes whose structures have been solved is
typically below 20%, the fold is predicted to be the same.
2.3. UDP-glucuronosyltransferases
2.3.1. Overview
UDP-glucuronosyltransferases (UGTs, EC 2.4.1.17) are major phase II enzymes that play
an important role in the detoxification of different endogenous and exogenous compounds,
e.g. drugs and environmental toxins, in humans. In the glucuronidation reaction glucuronic
acid from the donor UDP-glucuronic acid (UDPGA) is conjugated to a functional group,
mostly a hydroxyl, carboxyl, amino or thiol group on the activated target molecule
(aglycone), leading to the formation of O-, N-, or S-glucuronides, respectively (Fig. 2.3)
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(Dutton, 1980).  Some compounds, e.g. sulfinpyrazone or phenylbutazone, are metabolised
via uncommon C-glucuronidation pathway (Fig. 2.3) (Richter, et al., 1975; Kerdpin, et al.,

















































































































Figure 2.3 The O-,  N-,  S- and an example of C-glucuronidation reactions catalysed by UDP-
glucuronosyltransferases.
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By forming the -D-glucuronide, the polarity of the aglycone is increased and it can be
more easily excreted to bile or urine. This glucuronidation reaction is an important
detoxification pathway not only in humans, but also in other vertebrates. Usually the -D-
glucuronides are not biologically active, but in some cases increased toxicity of the
glucuronide has been reported (Radominska-Pandya, et al., 1999; King, et al., 2000; Tukey
and Strassburg, 2000; Fisher, et al., 2001; Ouzzine, et al., 2003). In addition to various
exogenous substrates, UDP-glucuronosyltransferases have an important role in the
elimination of several endogenous substrates, such as bile acids, steroid hormones and
especially bilirubin, the degradation product of haemoglobin. It is removed from the body by
the liver isoform UGT1A1. Mutations leading to non-functional or less active UGT1A1 can
cause hyperbilirubinemia, classified either as Crigler-Najjar or Gilbert syndrome. Untreated,
the severe form of hyperbilirubinemia can lead to death (Hirschfield and Alexander, 2006).
UGTs are mainly found in the liver, but they have also a very significant role in extra-hepatic
metabolism in the gastrointestinal tract and kidney (Fisher, et al., 2001; Tukey and
Strassburg, 2001; Soars, et al., 2002).
Human UGTs are around 530 amino acids in length, consisting of two approximately
similar-sized domains, like other GT-B fold glycosyltransferases (Radominska-Pandya, et
al., 1999) (Fig. 2.2B). The amino-terminal domain binds the aglycone and the carboxy-
terminal  domain  the  UDPGA (Mackenzie,  1990).  The  first  25  residues  or  so  form a  signal
sequence that directs the enzyme to the endoplasmic reticulum (ER) and is later cleaved off
(Kurkela, et al., 2003). The length of the mature protein is thus between 500 and 510
residues. The enzymes are 50 - 60 kDa in size and most of their mass is located in the ER
lumen; they have a single-pass 17-residue long transmembrane helix near the carboxy-
terminus and a 19 - 26 residue long cytosolic tail (Meech and Mackenzie, 1998;
Radominska-Pandya, et al., 1999). Mammalian UGTs may function as dimers or higher
oligomers (Radominska-Pandya, et al., 1999; Finel and Kurkela, 2008) (Fig. 2.4).
Figure 2.4 Schematic representation of human UGT topology. UGTs consist of two domains and
are predicted to function as dimers or higher oligomers. The amino-terminal domain binds the
aglycone and the carboxy-terminal domain the UDPGA cosubstrate; the catalytic site is placed
between the two domains. Most of the enzyme mass is located on the lumenal side of the endoplasmic
reticulum and the carboxy-terminal tail is on the cytosolic side of the membrane.
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In addition to the carboxy-terminal transmembrane helix, the amino-terminal domain
may also contain a membrane-attached region (Ciotti, et al., 1998). UGTs can be retained in
the ER even if the transmembrane and cytosolic parts are removed (Meech and Mackenzie,
1998; Ouzzine, et al., 1999a; Ouzzine, et al., 1999b). This amino-terminal membrane region
may be needed to help highly lipophilic substances to reach the active site (Radominska-
Pandya, et al., 2005). The region has also been suggested to play a role in dimerisation. This
conclusion was arrived at based on studies where residues 152 – 180 (the predicted
membrane embedded region) were deleted, almost completely abolishing the dimerisation of
UGT1A1 (Ghosh, et al., 2001).
Based on amino acid sequence and gene organisation, human UGTs can be divided into
two  major  subfamilies,  UGT1  and  UGT2,  or  alternatively  into  three  subfamilies,  UGT1A,
UGT2A and UGT2B (Mackenzie, et al., 1997; Mackenzie, et al., 2005) (Fig. 2.5). In the
UGT1 subfamily, the carboxy-terminal half of the protein is encoded by the shared exons 2
to 5 and is thus identical between all human UGT1-enzymes, whereas the variable amino-
terminal half, encoded by exon 1, is responsible for substrate specificity (Ritter, et al., 1992a;
Gong, et al., 2001). UGT2 enzymes are encoded by separate genes, except UGT2A1 and
UGT2A2, which probably use exon-sharing (Mackenzie, et al., 2005). 19 different human
UGTs have been recognised and thus far cDNAs for 17 functional human UGT-isoforms
have been isolated; several pseudogenes are also known (Mackenzie, et al., 2005; Sorich, et
al., 2008) (Fig. 2.5).
Figure 2.5 Phylogenetic tree of human UGT-enzymes showing evolutionary distances between
different isoforms. The alignment was made by ClustalW (Larkin, et al., 2007) and the tree was
constructed with the evolutionary Trace Server, TraceSuite II (Innis, et al., 2000).
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Because they are xenobiotic-metabolising enzymes, human UGTs have a wide variety of
substrates. Several hundred compounds have been identified as substrates for these enzymes
(Tukey and Strassburg, 2000) and the list is growing continually. Usually one isoform can
glucuronidate several substrates and one substrate can be glucuronidated by several isoforms
(Mackenzie, et al., 2000), though several isoform-specific substrates are also known (Court,
2005). Because of the difficulties in expressing these enzymes and purifying them in active
form, there is no complete three-dimensional structure of any mammalian UGT. The only
mammalian UGT crystal structure so far is a segment of the carboxy-terminal domain of
human UGT2B7 (Miley, et al., 2007). UGTs are suggested to function as dimers, but in the
absence of pure active enzyme this cannot be definitively proven. The structure of the
amino-terminal domain is not known. Structural information on how aglycone or UDPGA
binds is also not available.
2.3.2. Hyperbilirubinemia
250 to 350 mg of bilirubin (see Fig. 2.9), a degradation product of haemoglobin, is formed in
the human body per day. It is highly insoluble in water and therefore bound to albumin in the
circulation (Harb and Thomas, 2007). This unconjugated bilirubin is then transported to the
liver, where it is conjugated with glucuronic acid before excretion into bile. UGT1A1 is the
only significant bilirubin glucuronidating isoform in human (Bosma, et al., 1994; Bosma,
2003). Elevated levels of unconjugated bilirubin in the serum result in jaundice and a
condition known as unconjugated hyperbilirubinemia.
Three forms of unconjugated hyperbilirubinemia have been identified in man: Gilbert
syndrome and two types of Crigler-Najjar syndrome, CN-I and CN-II (Crigler and Najjar,
1952; Kadakol, et al., 2000; Bosma, 2003). Gilbert syndrome is a mild and very common
form of hyperbilirubinemia, leading to transiently elevated bilirubin levels (Strassburg,
2008). Five to ten percent of the Caucasian population are estimated to have Gilbert
syndrome (Owens and Evans, 1975; Kraemer and Klinker, 2002; Bosma, 2003). It is
commonly caused by additional TA nucleotides in the TATA box of the UGT1A1 gene
promoter region, leading to reduced UGT1A1 expression levels (Bosma, et al., 1995). This
allele, UGT1A1*28, reduces gene transcription to about 20% of the normal level (Bosma,
2003) and the hepatic UGT1A1 bilirubin activity is usually around 30% of normal
(Yamamoto, et al., 1998; Miners, et al., 2002; Rouits, et al., 2004). Gilbert syndrome can
also be caused by point mutations in the coding region of UGT1A1.
Crigler-Najjar syndrome (CN) leads to moderately or highly elevated unconjugated
bilirubin levels. CN-I is a rare, but very severe, form of hyperbilirubinemia, in which
UGT1A1 activity is undetectable (Francoual, et al., 2002). In CN-I patients serum bilirubin
values are usually above 350 µM and the amount of bilirubin conjugates in bile is extremely
low  (Jansen,  1999).  Without  treatment,  CN-I  disease  leads  to  death.  The  condition  can  be
completely cured only by liver transplantation. CN-II is a milder form of hyperbilirubinemia.
Serum bilirubin levels are usually below 350 µM and are lowered by phenobarbital treatment
(Jansen, 1999). The amount of bilirubin monoconjugates in bile is measurable, and low
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amounts of di-conjugates can also be detected (Jansen, 1999). UGT1A1 activity is
detectable, but below 10% of the normal level (Koiwai, et al., 1996).
Both CN-type diseases are inherited and caused by mutations in UGT1A1 coding exons.
Mutations are either in the amino-terminal domain, coded by exon 1, or in the carboxy-
terminal domain, coded by exons 2 – 5. As exons 2 – 5 are common to all members of the
UGT1 subfamily, mutations in these could lead to impaired activity of all the isoforms of the
subfamily (Jansen, 1999). The first mutations leading to CN-I syndrome were identified in
1992 (Bosma, et al., 1992; Ritter, et al., 1992b) and to CN-II syndrome in 1993 (Aono, et al.,
1993; Bosma, 2003). Several mutations leading to either Gilbert, CN-I or CN-II type
disorders have been detected in the human UGT1A1 gene (113 UGT1A1 variant forms have
been reported so far, of which 74 are CN variants). The UDP-Glucuronosyltransferase
Alleles Nomenclature page (http://www.pharmacogenomics.pha.ulaval.ca/sgc/ugt_alleles/)
and references therein contain the most up-to-date summary of the reported mutations.
Y486D mutation
One of the first mutations identified in patients is Y486D, which leads to a mild form of
hyperbilirubinemia (Aono, et al., 1993; Maruo, et al., 1998). In the homozygous form it has
been found in both Gilbert- and CN-II-type syndrome patients, the variation probably being
due to other genetic differences (Takeuchi, et al., 2004). Normally these conditions are not
accompanied by many symptoms, but the mutation may contribute to the toxic effects of
certain medications. One example is the antitumor agent irinotecan (CPT-11), which is
metabolised to 7-ethyl-10-hydroxycamptothecin (SN-38) (Jinno, et al., 2003). SN-38 is the
active metabolite and is further glucuronidated by UGT1A1. The effect of the Y486D
mutation in UGT1A1 on SN-38 glucuronidation was investigated with COS-1 cells
expressing the mutant protein. The glucuronidation efficiency was drastically decreased
(Jinno, et al., 2003). The equivalent mutation was also studied using the UGT1A1 and
UGT1A6 (Y485D mutation in UGT1A6) isoforms expressed in COS-7 cells. The
glucuronidation of 2-amino-5-nitro-4-trifluoromethylphenol (a major metabolite of
flutamide, a nonsteroidal anti-androgenic agent) was about 12% of the wild type activity in
the UGT1A1 mutant, but below 1% in the UGT1A6 mutant (Ito, et al., 2002). Overall, the
effect  of  the  Y D mutation on the glucuronidation rate varies depending on the substrate
and the isoform studied (Udomuksorn, et al., 2007). Usually the glucuronidation rate is
substantially reduced, except for UGT1A9, where even increased glucuronidation rates have
been reported (Kurkela, et al., 2004).
2.3.3. Oligomerisation of mammalian UGTs
Mammalian UGTs, like many other single-pass membrane proteins, are thought to function
as dimers or oligomers. Several different methods have been used in attempts to clarify the
oligomeric state of these enzymes. Based on gel filtration and polyacrylamide gradient gel
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electrophoresis, it was proposed at the beginning of the 1980s that rat liver UGTs exist as
units larger than monomers (Matern, et al., 1982). Radiation inactivation experiments in
1984 suggested that UGTs may exist as monomers or oligomers consisting of up to four
subunits (Peters, et al., 1984). In this method, membranes containing the protein are exposed
to ionizing radiation; the degree of inactivation is proportional to the radiation dose and the
size of the molecule (Radominska-Pandya, et al., 2005; Finel and Kurkela, 2008). Later
studies based on this method suggested that monoglucuronide formation of phenols is
catalysed by dimeric UGTs, and diglucuronide formation by tetrameric UGTs (Gschaidmeier
and Bock, 1994).
In 1997 Meech and Mackenzie proposed that UGTs form catalytically active dimers via
their amino-terminal domains. This conclusion was derived from mutation, co-expression
and SDS-PAGE analyses (Meech and Mackenzie, 1997). They showed that two inactive
units of UGT2B1 can become active through oligomerisation. Evidence for oligomerisation
also came from work in which a human UGT1A1 nonsense mutation led to the formation of
inactive enzyme and caused Crigler-Najjar syndrome type II (CN-II). The inactive mutant
form was shown to inhibit the activity of the full-length UGT1A1, indicating an interaction
between them (Koiwai, et al., 1996).
Immunopurification studies with rat hepatic microsomes suggested that there were
protein-protein interactions between UGT1s and UGT2B1 (Ikushiro, et al., 1997). In the
study, UGT1 isoforms were bound to a Sepharose column which was conjugated with UGT1
carboxy-terminal-specific anti-peptide antibodies. UGT2B1 was shown to co-elute with
UGT1-isoforms. Chemical cross-linking studies with bismaleimidohexane (BMH), which is
reactive towards sulfhydryl groups, suggested that UGTs form heterodimers (Ikushiro, et al.,
1997). Studies using gel permeation chromatography of solubilised microsomes implied that
UGT1A1 is a dimer in solution and the yeast two-hybrid system indicated that it has
intermolecular interactions only with itself (Ghosh, et al., 2001). Co-immunoprecipitation
studies using human liver microsomes suggested interactions between UGT1A1, UGT1A6
and UGT2B7 (Fremont, et al., 2005) and the same method, combined with in vivo
fluorescence resonance energy transfer (FRET), was used to demonstrate protein-protein
interactions in live COS cells (Operana and Tukey, 2007). In this study, Operana and Tukey
(2007) showed that all the UGT1 subfamily members self-oligomerise (homodimerise) and,
in  contrast  to  a  previous  study  (Ghosh, et al., 2001), UGT1A1 was also shown to form
hetero-oligomers with UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9 and
UGT1A10.
 Oligomerisation of UGTs has also been studied with recombinant enzymes expressed in
Sf9 insect cells (Kurkela, et al., 2003). Both His- and HA-tagged human UGT1A9-isoforms
were produced and the solubilised membrane extract was loaded onto an IMAC-column,
which binds His-tagged proteins. When His-tagged proteins were eluted with imidazole, HA-
tagged enzymes were also detected in the same fractions, demonstrating an interaction
between the monomers (Kurkela, et al., 2003).
Overall, it is now quite clear that the active units of UGTs are complexes larger than
monomers. Nowadays they are often assumed to be dimers (Kurkela, et al., 2003; Kurkela, et
al., 2004a; Kurkela, et al., 2004b; Operana and Tukey, 2007), even though higher oligomers
cannot be excluded (Finel and Kurkela, 2008). Nonetheless, the question is more
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complicated if we try to investigate the role and physiological significance of homo- or
hetero-oligomerisation in vivo.
The formation of hetero-oligomers has been reported in several studies (Meech and
Mackenzie, 1997; Ikushiro, et al., 1997; Ishii, et al., 2004; Operana and Tukey, 2007), even
though in one study the UGT1A1 isoform was shown to form only homo-oligomers (Ghosh,
et al., 2001). The first study indicating that hetero-oligomerisation can affect substrate
specificity was done on morphine with guinea pig enzymes UGT2B21 and UGT2B22 (Ishii,
et al., 2001). The same group confirmed the results later by showing that hetero-
oligomerisation enhances chloramphenicol glucuronidation (Ishii, et al., 2004). Hetero-
oligomerisation between UGT1A4 and a truncated form of UGT1A9 (UGT1A9 from which
the carboxy-terminal transmembrane helix and the following cytosolic tail has been removed
- referred to as 1A9Sol) was shown to affect substrate specificity (Kurkela, et al., 2004a). In
this work, UGT1A4, which glucuronidates entacapone at nonsignificant rates, was co-
expressed with 1A9Sol in Sf9 insect cells. The decrease in the Km of entacapone was related
to the probability of hetero-oligomer formation, thus revealing important monomer-monomer
interactions within the UGTs (Kurkela, et al., 2004a). Hetero-oligomerisation was also
reported to affect the kinetic parameters (Km and Vmax) in studies where UGT1A1, UGT1A4
and UGT1A6 were co-expressed in HEK293 cells. Km and  Vmax increased or decreased
depending on the isoform and substrate used (Fujiwara, et al., 2007a). Fujiwara et al. (2007a;
2007b) expressed double isoforms of UGT1A1/UGT1A9, UGT1A4/UGT1A9 and
UGT1A6/UGT1A9 in HEK293 cells and analysed the interactions. UGT1A1, UGT1A4 and
UGT1A6 acquired thermal stability and resistance to detergent when co-expressed with
UGT1A9 and their kinetic parameters were also affected (Fujiwara, et al., 2007b). Quite
recently, alternative splicing variants of human UGT1A1 have been found in several tissues.
These inactive variants decrease the activity of normal UGT1A1 (UGT1A1_i1) through
direct protein-protein interactions (Lévesque, et al., 2007; Girard, et al., 2007). Thus hetero-
oligomerisation may affect UGT function, enzymatic characteristics and substrate selectivity
in vivo (Operana and Tukey, 2007; Fujiwara, et al., 2007b), and could also play a negative
regulatory role in the human glucuronidation pathway (Lévesque, et al., 2007; Girard, et al.,
2007).
2.3.4. Co-substrate binding
The functional unit of human UGTs consists of two or more monomers, and the monomeric
unit of mammalian UGTs consists of two domains. The more conserved carboxy-terminal
domain of UGTs binds the co-substrate UDPGA and the more variable amino-terminal
domain the aglycone. The 44-residue long consensus motif (PS00375), which is thought to
be involved in binding the UDP moiety of the nucleotide sugar, is located in the carboxy-
terminal half of all UDP-glycosyltransferases (Mackenzie, et al., 1997) (Fig. 2.6). It can be
found in mammalian, plant and bacterial species (Mackenzie, et al., 1997; Ross, et al., 2001).
It also should be noted that, in the human UGT1A subfamily, the carboxy-terminal domain is
encoded by the shared exons 2 to 5, and is thus totally identical among the different isoforms
of this subfamily. The carboxy-terminal domains of UGT2 enzymes, except for UGT2A1
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UGT2A2, are encoded by separate exons, but the amino acid sequence identity between
UGT1 and UGT2 enzymes in this domain is still about 60% and the similarity over 70%.
[FW] - x(2) - [QL] - x(2) - [LIVMYA] - [LIMV] - x(4,6) - [LVGAC] - [LVFYAHM] -
[LIVMF] - [STAGCM] - [HNQ] - [STAGC] - G - x(2) - [STAG] - x(3) - [STAGL] -
[LIVMFA] - x(4,5) - [PQR] - [LIVMTA] - x(3) - [PA] - x(2,3) - [DES] - [QEHNR]
Figure 2.6 Consensus sequence found in all UDP-glycosyltransferases (Prosite code PS00375).
This motif is suggested to be involved in co-substrate binding and is part of the carboxy-terminal
domain.
The glucuronidation reaction takes place in the lumen of the endoplasmic reticulum. The
hydrophilic UDPGA sugar synthesised in the cytosol has to reach the active site. Current
data suggest that independent UDPGA transporters supply UDPGA to the catalytic site
(Kobayashi, et al., 2006).
The first suggestion that the UDPGA binding site is in the carboxy-terminal domain was
based on studies with chimeric UGTs (Mackenzie, 1990). Later, results from photoaffinity
labelling with UGT2B4 fusion peptides confirmed that the UDPGA binding site is between
residues 299 and 446 (Pillot, et al., 1993). This was further narrowed to residues 350 - 400
using photolabelled UGT1A6, and sequence and structure comparisons (Radominska-
Pandya, et al., 1999). However, photoaffinity labelling, inhibitor studies and sequence
alignments suggest that UDPGA interacts not only with the carboxy-terminal but also with
the amino-terminal domains of UGTs (Radominska-Pandya, et al., 1999). The same
conclusion was drawn from studies where a homology model of UGT1A1 was built using
the plant protein UGT71G1 as a template and the UDPGA co-substrate was docked to the
model (Li and Wu, 2007; Locuson and Tracy, 2007).
Comparison of the carboxy-terminal domain structure of UGT2B7 to the other GT1
family enzyme structures suggests that UDPGA binds to the same site as co-substrate in
these enzymes (Miley, et al., 2007) (Fig. 2.7). The predicted UDPGA binding site in UGTs
seems to be remarkably similar to the UDP-glucose binding site in other GT1 enzymes
(Mulichak, et al., 2001; Shao, et al., 2005; Offen, et al., 2006; Brazier-Hicks, et al., 2007; Li,
et al., 2007b; Mittler, et al., 2007). This is reasonable, because UDP-glucose and UDP-
glucuronic acid are very similar, differing only at the 6-position of the sugar (Fig. 2.8). The
RMSD of the carboxy-terminal segment of human UGT2B7 compared to those GT1
structures that use UDP-glucose as a co-substrate is around 2 Å (Miley, et al., 2007). The
other co-substrates used in the GT1 family are UDP-rhamnose (Jones, et al., 2003) and
various TDP-derivatives (Mulichak, et al., 2003; Mulichak, et al., 2004; Mittler, et al.,
2007). CalG3, calicheamicinone-4,6-dideoxy-4-hydroxylamino- -D-glucosyltransferase, is
quite promiscuous for sugar donors and has been demonstrated to accept ten alternative
NDP-sugar donors (Zhang, et al., 2008).
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 L354
                W353 Q356 H362     H371    E379           D395 Q396
                                                         
UGT2B7   : LNTRLYKWIPQNDLLGHPKTRAFITHGGANGIYEAIYHGIPMVGIPLFAD----QPD : 401
UGT2B10  : LNTRLYKWIPQNDLLGHPKTRAFITHGGANGIYEAIYHGIPMVGIPLFFD----QPD : 400
UGT1A    : NNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGD----QMD : 398
GtfB     : ADCFAIGEVNHQVLFGR--VAAVIHHGGAGTTHVAARAGAPQILLPQMAD----QPY : 335
GtfA     : ADCFVVGEVNLQELFGR--VAAAIHHDSAGTTLLAMRAGIPQIVVRRVVDNVVEQAY : 324
GtfD     : DDCFAIDEVNFQALFRR--VAAVIHHGSAGTEHVATRAGVPQLVIPRNTD----QPY : 336
OleI_bac : PNVEVHQWVPQLDILTK--ASAFITHAGMGSTMEALSNAVPMVAVPQIAE----QTM : 355
OleD_bac : DNVEVHDWVPQLAILRQ--ADLFVTHAGAGGSQEGLATATPMIAVPQAVD----QFG : 333
UGT72B1  : G-FVIPFWAPQAQVLAHPSTGGFLTHCGWNSTLESVVSGIPLIAWPLYAE----QKM : 391
UGT71G1  : GKGMICGWAPQVEVLAHKAIGGFVSHCGWNSILESMWFGVPILTWPIYAE----QQL : 384
UGT85H2  : DRGLIASWCPQDKVLNHPSIGGFLTHCGWNSTTESICAGVPMLCWPFFAD----QPT : 405
VvGT1    : GYGMVVPWAPQAEVLAHEAVGAFVTHCGWNSLWESVAGGVPLICRPFFGD----QRL : 377
CalG3    : RNVRAVGWTPLHTLLRT--CTAVVHHGGGGTVMTAIDAGIPQLLAPDPRD----QFQ : 333
UrdGT2   : VPQARVGWTPLDVVAPT--CDLLVHHAGGVSTLTGLSAGEPQLLIPKGSV----LEA : 300
Figure 2.7 Partial sequence alignment of 14 GT1 family enzymes. UGT2B7, UGT2B10
and UGT1A are human enzymes and the other eleven are crystallised glycosyltransferases
whose complete structures have been solved. Shown are residues from 300 to 400, which is
the most conserved region in all GT1 enzymes. The carboxy-terminal domain is totally









































glucuronic acid phosphate nucleotideglucose phosphate nucleotide
Figure 2.8 Chemical structures of UDP-glucose and UDP-glucuronic acid.
The key conclusions from the different modelling studies concerning the specific residues
making contacts with UDPGA are quite consistent with each other (Miley, et al., 2007; Li
and Wu, 2007; Locuson and Tracy, 2007). In addition, the UDPGA binding site has been
studied by chemical modification (Ouzzine, et al., 2000) and by site-directed mutagenesis
(Miley, et al., 2007). Miley et al. (2007) mutated several residues in the predicted UDPGA
binding region of UGT2B7 and studied the activities of mutants in single-point activity
measurements. They divided the predicted interacting residues into three different groups:
residues interacting with 1) nucleotide, 2) phosphate, or 3) glucuronic acid (Fig. 2.8). The
residues interacting with phosphate or glucuronic acid seemed to be more critical for activity
than those interacting with the nucleotide. Q356 is predicted to make contact with the uracil
base; W353 is predicted to stack over the uracil ring and E379 is predicted to hydrogen bond
to the ribose 2’-OH. The main chain carbonyl and -NH of L354 (Locuson and Tracy, 2007)
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and side chain of R335 have been suggested to make contacts to the uridine group (Miley, et
al., 2007; Li and Wu, 2007; Locuson and Tracy, 2007). These interactions have been found
in  several  other  GT-B  enzyme  structures  (Shao, et al., 2005; Offen, et al., 2006; Brazier-
Hicks, et al., 2007; Li, et al., 2007b; Bolam, et al., 2007). Mutations in residues W356, Q359
and R338 (W353, Q356 and R335 in UGT1A6 numbering), predicted to make contacts to
uridine, had only small or moderate effects on the UGT2B7 glucuronidation activity (Miley,
et al., 2007).
 The most conserved residue in the predicted UDPGA binding area is H371 (UGT1A6
numbering) (Fig. 2.7). It has been suggested to interact with the diphosphate moiety of
UDPGA (Miley, et al., 2007; Li and Wu, 2007; Locuson and Tracy, 2007) and may have a
role in stabilising the leaving group during catalysis (Radominska-Pandya, et al., 2005).
Based on mutational studies, H362 has also been suggested to interact with UDPGA
(Ouzzine, et al., 2000), but this has not been confirmed by other studies. Residues D395 and
Q396, which are highly conserved among GT1 enzymes, are predicted to interact with the
3’O and 4’O of the glucuronic acid. Mutating the equivalent residues in UGT2B7 (D398,
Q399) had a drastic effect on enzyme activity (Miley, et al., 2007). The high conservation of
the corresponding residues among all vertebrate UGTs led to the suggestion that they play an
important role in the recognition of the donor molecule (Li and Wu, 2007). In a very recent
paper, based on biochemical experiments and homology-based modelling using E. coli UDP-
galactose 4-epimerase as a template, residues K314 and K404 in UGT1A10 were suggested
to be involved in UDPGA interactions (Banerjee, et al., 2008). Nonetheless, the specific role
of these residues has not been discussed in any other papers.
Based on photoaffinity labelling studies, the residues in the amino-terminal domain have
also been proposed to make contacts to UDPGA (Radominska-Pandya, et al., 1999). This
view was supported by the structures of UDP-glucose:GT1-enzyme complexes.  Suggestions
that the amino-terminal domain residues G36, S37 and R195 in UGT1A1 are involved in
UDPGA binding have only recently been presented (Li and Wu, 2007; Locuson and Tracy,
2007), and their roles have yet to be confirmed by mutational or biochemical studies.
Generally the effect of mutations in the UDPGA binding area on activity seems to depend on
substrate, implying that positioning of the UDPGA is more critical for some aglycones than
for others.
2.3.5. Aglycone binding
As described above, the carboxy-terminal domain binds UDPGA. Conversely, the amino-
terminal domain, formed from the first 260 residues of the mature protein, binds the
aglycone (Mackenzie, 1990) and so is responsible for substrate specificity. The substrates
typically contain aromatic ring structures and are highly hydrophobic; some are even
classified as lipids (Fig. 2.9). An amino-terminal membrane-attached region, suggested to be
located between residues 140 – 240 (Radominska-Pandya, et al., 2005), may be needed to
help highly lipophilic substances reach the active site. The more specific location of this
region is not known, but based on analysis by the computer program RAOARGOS (Argos, et
al., 1982) the membrane-attached region has been suggested to be located between residues
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159 – 177 (UGT1A1 numbering) (Ciotti, et al., 1998). However, this needs to be confirmed
by further studies.
An unusual feature of enzymes that metabolise xenobiotics is their promiscuity, and
hence the aglycone binding site cannot be highly selective. Instead, each isoform has to be
able to accept a wide range of molecules ranging from single phenols to long chain fatty
acids and multi-ring structures (Fig. 2.9). In addition, all UGTs have different and usually
partly overlapping substrate specificities, implying that the most variable residues may have
an important role in substrate specificity and selection. The most diverse region for all UGTs
is the area between residues 90 and 190 (Radominska-Pandya, et al., 1999). By constructing
UGT2B7-UGT2B15 chimeras, Lewis et al. have in fact shown that residues 61 – 194 of































Figure 2.9  Examples of the chemical structures of UGT1A1 substrates showing the structural
diversity of aglycones glucuronidated by one UGT isoform. Arrows indicate the sites of the
glucuronidation.
Photoaffinity labelling, NMR, mutational studies, studies with chimeric constructs and
modelling have been used to define the aglycone binding site and the specific residues
involved in binding. The fluorescent photoactive compound 7-azido-4-methylcoumarin
(AzMC), structurally related to the UGT1A6 substrate 4-methylumbelliferone (4-MU), was
used to examine the phenol binding site in human UGT1A6. The results suggested that, a
conserved KxxPxP motif, residues 76 – 81, was involved in aglycone binding (Battaglia, et
al., 1998; Senay, et al., 1999). Dubois et al. (1999) studied two highly homologous human
isoforms, UGT2B15 and UGT2B17, which differ by only 29 residues. Both enzymes can
glucuronidate steroids at the 17 -OH position, but only UGT2B17 can glucuronidate C19
steroids at the 3 -OH position. Several individual mutations in UGT2B17 abolished activity
completely, whereas, in UGT2B15, only mutations at residues 121 and 181 impaired
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catalytic function. Dubois et al. (1999) suggested that these residues are in the active site and
interact with the substrate molecule. The S121W mutation in UGT2B17 altered the
specificity towards the 3 -OH in C19 steroids, whereas the W121S mutation in UGT2B15
did  not  confer  3 -OH  C19 steroid specificity indicating that, despite the high similarity
between these isoforms, different residues are involved in determining the steroid specificity
(Dubois, et al., 1999).
Coffman et al. ( 2001; 2003) made three different maltose binding protein (MBP) fusion
constructs of UGT2B7 and analysed them by NMR spectroscopy. The binding properties
were analysed by examining the effect of the protein constructs on the NMR spectra and
relaxation rates of the morphine. The constructs containing the UGT2B7 residues 24 – 118
or 84 – 118 bound the morphine, whereas the construct containing residues 24 – 96 did not.
Based on this, the authors modelled a binding pocket within residues 96 – 101, which was
supported by mutational analysis.
Barre et al. (2007) studied residue 33 in UGT2B4 and UGT2B7. The residue in this
position is not conserved; it is glycine in UGT1s, phenylalanine in UGT2B4 and tyrosine in
UGT2B7. Mutational analysis indicated that the presence of an aromatic residue at position
33 is important for the activity of both UGT2B4 and UGT2B7. The substrate selectivities of
UGT1A3 and UGT1A4, which share 93.4% sequence identity, were investigated by
constructing chimeras and by mutational studies (Kubota, et al., 2007; Li, et al., 2007a).
UGT1A3 glucuronidates phenolic compounds, whereas UGT1A4 tends to glucuronidate
amine compounds (Green, et al., 1995; Green, et al., 1998; Green and Tephly, 1998). Within
the first 44 residues, UGT1A3 and UGT1A4 differ only in positions 36 and 40, being
isoleucine and histidine in UGT1A3 and threonine and proline in UGT1A4, respectively.
Introducing the I36T and H40P mutations to UGT1A3 reduced the glucuronidation of
phenolic compounds remarkably, whereas introducing the T36I and P40H mutations to
UGT1A4 reduced the activity towards tertiary amines. In contrast, the H40P mutation in
UGT1A3 increased the glucuronidation of tertiary amines and the T36I mutation in UGT1A4
increased the glucuronidation of planar phenols. These residues thus seem to have a critical
role in the differing phenol and tertiary amine aglycone substrate selectivities (Kubota, et al.,
2007). Similar conclusions regarding the role of residue 40 were also obtained in another
study (Li, et al., 2007a).
R52 and H54, located in a conserved amino-terminal region in UGT1A6, were studied by
site-directed mutagenesis. They seem to be important for function and integrity, but are not
directly involved in aglycone binding (Senay, et al., 1997). In UGT1A10, the F90MVF93
motif has been shown to be important in binding phenolic compounds (Xiong, et al., 2006)
and estrogen (Xiong, et al., 2006; Starlard-Davenport, et al., 2007). F90 was especially
important and may form hydrophobic aromatic ring stacking interactions with the phenolic
ring of the aglycone (Xiong, et al., 2006; Miller, et al., 2008). The motif was identified using
photoaffinity labelling followed by LC-MS/MS analysis, and by site-directed mutagenesis
(Xiong, et al., 2006). The role of F90 is consistent with the model of Li and Wu (2007),
which predicts that the equivalent residue in UGT1A1, F92, interacts with the aglycone.
A very recent paper suggested that UGT2B7 had two binding sites for each substrate
studied (AZT, 4-MU, 1-NP) maybe reflecting the dimer formation. The results are based on
an analysis using multisite and empirical kinetic models. In addition, the data suggest the
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existence of multiple effector sites (Uchaipichat, et al., 2008) thus making the kinetic and
inhibitor studies of UGTs still more complicated.
Figure 2.10  Aglycone binding residues studied in human UGTs. All the residues or motifs presented
here are suggested to interact with the aglycone except for residues 52 and 54 in UGT1A6.
2.3.6. Binding order in UGTs
For an enzyme that takes two substrates (UDPGA and aglycone in case of UGTs) and forms
two products (glucuronide and UDP), the enzyme mechanism can be classified either as
sequential or ping-pong. Two-substrate and two-product reactions are usually termed bi-bi
reactions.  In  a  sequential  mechanism,  both  substrates  have  to  combine  with  the  enzyme,
forming a ternary complex, before the reaction can proceed. Sequential mechanisms can be
either compulsory ordered, where a particular substrate always binds first, or random
ordered, in which the binding order of the two substrates varies. In a ping-pong mechanism,
the second substrate can bind only after the first substrate is released.
As early as 1972 bisubstrate kinetics and inhibition studies with guinea-pig bilirubin
UGT, equivalent to the human UGT1A1 isoform, led to suggestions that the mechanism was
sequential compulsory ordered bi-bi (Potrepka and Spratt, 1972). Potrepka and Patt
suggested that UDPGA bound first and bilirubin afterwards, leading to formation of the
ternary complex (Potrepka and Spratt, 1972). During the same year, another group came to a
different conclusion, suggesting that the reaction is sequential random ordered bi-bi (Vessey
and Zakim, 1972). Their conclusion was based on bisubstrate kinetics, inhibition and isotope
exchange studies with bovine and guinea-pig liver microsomes using paranitrophenol as the
aglycone (Vessey and Zakim, 1972). A few years later Sanchez and Tephly (1975)
concluded that the plausible mechanism for morphine glucuronidation in rat hepatic
microsomes is sequential ordered, with UDPGA binding first and morphine binding second.
Koster and Noordhoek suggested the same mechanism (sequential ordered) for rat intestinal
microsomes, but an opposite binding order: 1-naphthol binding first and UDPGA second
(Koster and Noordhoek, 1983).
Bisubstrate kinetics, product inhibition and dead-end competitive inhibition studies were
performed on two purified rat liver steroid UGTs. Testosterone and androsterone were the
substrates. The results were consistent with a random ordered sequential kinetic mechanism
(Falany, et al., 1987). Interestingly, the same group had earlier suggested a compulsory
ordered sequential mechanism for morphine glucuronidation in hepatic microsomes
(Sanchez and Tephly, 1975). Two-substrate kinetic analysis of purified human liver
hyodeoxylcholic-acid:UDP-glucuronosyltransferase was consistent with a sequential
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mechanism (Matern, et al., 1991), but these studies did not include experiments which could
differentiate between compulsory or random ordered binding. Bisubstrate reaction kinetics
and inhibition studies with partially purified UGT indicated that the reaction occurs via a
random ordered sequential mechanism (Yin, et al., 1994).
Most of the studies mentioned above were performed using rat hepatic microsomes.
Fourteen different rat UGT-isoforms are known today
(http://som.flinders.edu.au/FUSA/ClinPharm/UGT/) and thus several isoforms may
contribute to the glucuronidation process, interfering with the interpretation of kinetic data.
In man, bilirubin and morphine are quite specific substrates glucuronidated only by one
UGT-isoform, whereas 1-naphthol and paranitrophenol are glucuronidated by several UGT-
isoforms. In addition, the kinetics may be distorted in purified protein preparations in which
the enzyme has been removed from its normal lipidic environment. These factors may
explain the variable results.
The matter was finally laid to rest decisively by Luukkanen and co-workers (2005). They
studied eight recombinant human UGTs of the 1A subfamily by bisubstrate kinetics and
inhibition studies. This was the first study using recombinant enzymes, allowing
measurements of individual isoforms in membranes. The results clearly showed that the
mechanism is compulsory ordered bi-bi and that UDPGA binds first.
2.3.7. Catalytic mechanism and residues in GT1 enzymes
When a new glycosidic bond forms, two stereochemical outcomes are possible: the





















Figure 2.11 Two main catalytic mechanisms of glycosyltransferases: retention or inversion of the
anomeric configuration. Human UGTs are inverting glycosyltransferases, like all other members of
the GT1 family.
Human UGTs, as well as all the other GT1 family members, are inverting
glycosyltransferases (Johnson and Fenselau, 1978) that use a direct displacement SN2-
reaction mechanism (Yin, et al.,  1994).  An active  site  residue  functions  as  a  catalytic  base
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that deprotonates the substrate for a nucleophilic attack on the anomeric carbon of the sugar
donor (Lairson, et al., 2008).
However, the catalytic residues in GT1 family enzymes seem not to be conserved. The
first three solved GT1 family structures, GtfA (Mulichak, et al., 2003), GtfB (Mulichak, et
al., 2001) and GtfD (Mulichak, et al., 2004) are bacterial enzymes involved in antibiotic
vancomycin synthesis. Structural, kinetic and mutational analyses suggest that these enzymes
use aspartate (D13) as the catalytic base (Fig. 2.12) (Mulichak, et al.,  2004).  However,  a
number of plant and other glycosyltransferases use a serine protease-like mechanism instead,
as can be seen from the sequence alignment (Fig. 2.12) (Shao, et al., 2005; Offen, et al.,
2006; Li, et al., 2007b; Brazier-Hicks, et al., 2007; Bolam, et al., 2007; Zhang, et al., 2008).
A histidine residue near the amino-terminus (H20 in VvGT1) and an adjacent aspartate or
glutamate (D119 in VvGT1) function as a “catalytic dyad” (Fig. 2.12). The corresponding
histidine residue (H18) is also found in E. coli MurG, which is a member of the distantly
related GT28 family. The H18A mutation impairs the catalytic efficiency of MurG
drastically (Hu, et al., 2003; Crouvoisier, et al., 2007). The authors, however, suggest that
E125 plays a catalytic role in this enzyme (Crouvoisier, et al., 2007).
Interestingly, UDP-isoflavone 7-O-glucosyltransferase, GmIF7GT, has a conserved His-
Asp dyad, but these residues were shown to be unimportant for the enzyme activity. Instead,
mutational analysis suggested that an acidic residue at position 392 is essential for catalysis
in this enzyme (Noguchi, et al., 2007). The C-C bond-forming glycosyltransferase UrdGT2
has been suggested to use aspartate D137 as the activator for C-C bond formation (Mittler, et
al., 2007).
D13
GtfB     : -MRVLLATCGSRGDTEPLVALA...-EGCAAVVTTGLLAAAIGVRSVAEKLGIPYF : 121
GtfA     : -MRVLITGCGSRGDTEPLVALA...-EGCDAVVTTGLLPAAVAVRSMAEKLGIPYR : 120
GtfD     : -MRVLLSVCGTRGDVEIGVALA...-EGCAAVVAVGDLAAATGVRSVAEKLGLPFF : 122
H20 119
                        
VvGT1    : NPHVAVLAFPFSTHAAPLLAVV...--G-RPVSCLVADAFIWFAADMAAEMGVAWL : 137
UGT72B1  : TPHVAIIPSPGMGHLIPLVEFA...----RLPTALVVDLFGTDAFDVAVEFHVPPY : 135
UGT71G1  : NSELIFIPAPGIGHLASALEFA...------VVGLVLDFFCVSMIDVGNEFGIPSY : 139
OleI_bac : TPHISFFNIPGHGHVNPSLGIV...AYADDRPDLIVYDIASWPAPVLGRKWDIPFV : 134
OleD_bac : PAHIAMFSIAAHGHVNPSLEVI...AYADDIPDLVLHDITSYPARVLARRWGVPAV : 129
UGT85H2  : KPHVVMIPYPVQGHINPLFKLA...--NVPPVTCLVSDCCMSFTIQAAEEFELPNV : 143
CalG3    : HMRVLFVSSPGIGHLFPLIQLA...LVDDYRPDLVVYEQGATVGLLAADRAGVPAV : 155
Figure 2.12  Sequence alignment of ten GT1 enzymes and their catalytic residues.
2.3.8. Catalytic mechanism and residues in UGTs
It was suggested as early as 1958 that the glucuronidation mechanism is an SN2 type
substitution reaction with nucleophilic attack of the aglycone on the electrophilic C1 atom of
glucuronic acid (Axelrod et al., 1958). This was later confirmed by bisubstrate kinetics and
inhibition studies (Johnson and Fenselau, 1978). More detailed suggestions of the residues
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involved in catalysis came much later. In 1994, Battaglia et al. (1994a; 1994b) showed that
histidine and a carboxyl group are involved in catalysis in human UGTs. These studies were
based on experiments on UGT1A6 using chemical modification reagents. Later, based on
inhibition of the enzyme activity by the histidyl-selective reagent diethyl pyrocarbonate
(DEPC), H370 in UGT1A6 (correct numbering H371) was suggested to function in catalysis
(Ouzzine, et al., 2000).
The  identity  of  the  catalytic  residue  was  revisited  when  two  new  plant  GT1  structures
became available (Shao, et al., 2005; Offen, et al., 2006). Miley et al. (2007) used the plant
VvGT1 structure to generate a homology model of UGT2B7. The authors suggested that
UGTs, like several other GT1 enzymes (see previous section), use a serine hydrolase-like
catalytic mechanism where histidine and aspartate function as a catalytic dyad. Hence H35 of
UGT2B7 deprotonates a phenolic group of the acceptor ligand, assisting a nucleophilic
attack at the C1 atom of glucuronic acid. The protonated histidine is stabilised by the
adjacent D151. This view was supported by mutational analysis (Miley, et al., 2007). Two
different groups published a homology model of UGT1A1 at almost the same time and came
to similar conclusions, namely that the active site residues are H39 and D151 in UGT1A1 (Li
and Wu, 2007; Locuson and Tracy, 2007). However, Li et al. (2007a) suggested, based on
extensive site-directed mutagenesis and kinetic measurements, that D150 (UGT1A6
numbering) plays a major catalytic role in the UGT1A family, and H38 is involved in
defining the substrate specificity rather than in catalysis.
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3. Aims of the study
The main aim of my studies was to obtain structural and functional information on
human UDP-glucuronosyltransferases. My specific goals were:
1) To understand homo- and hetero-oligomerisation of human UGTs and its possible
physiological significance.
2) To identify residues involved in UDPGA binding.
3) To identify residues involved in aglycone binding and recognition.
4) To clarify the mechanism of glucurondiation:
a. To identify residues involved in catalysis and the catalytic mechanism.
b. To understand the differences between N- and O-glucuronidation.
These questions were approached by co-expression, mutation, single-point activity,




Experimental methods used in this thesis work are listed in Table I. Detailed descriptions of
the methods in this study are found in the original publications I-IV or references therein.
Table 1. List of the methods used in this thesis. Numbers I-IV refer to the original
publications.
Method Study
Molecular biology DNA sequencing I, II, III, IV
PCR II, III, IV
Cloning I, II, III, IV
Expression I, II, II, IV
Co-expression I
Site-directed mutagenesis I, II, III, IV
Enzymatic analysis Single-point activity I,II, III, IV
Kinetics I, II, III, IV
Bisubstrate kinetics II
HPLC I, II, IV
UPLC IV
TLC III
Protein Dot blot I, II, IV
Protein purification I
Western blot III
Membrane preparation I, II, III, IV
Homology modelling II, III
Sequence comparisons II, III, IV
Software Clustal W II, III, IV
GeneDoc II, III, IV
GraphPad Prism I, II, IV
InsightII II, III




Table 2. List of the substrates used in the thesis and the publications in which they were used.












































































































The activity measurements with the substrates marked with a * were performed in a
collaborator’s laboratory

























Vmax = maximum velocity
[S] = substrate concentration
Km = Michaelis constant
[UDPGA] = UDPGA concentration
[AGLY] = aglycone concentration
Kd(UDPGA) = dissocation constant for UDPGA
Km(UDPGA) = Michaelis constant for UDPGA
Km(AGLY) = Michaelis constant for aglycone
Ki = dissociation constant for inhibitor
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5. Results and Discussion
5.1. Monomer-monomer interactions and their significance
(Study I)
The conserved tyrosine residue (Y486 in UGT1A1) is located in the carboxy-terminal
domain of human UGTs, just before the predicted trans-membrane helix. The Y486D
mutation in human UGT1A1 is a pathological mutation leading to Crigler-Najjar syndrome
type II (Aono, et al., 1993). When this mutation is present all the UGT1A enzymes carry it
because they all share exons 2 to 5 and have identical carboxy-terminal domains.
We investigated the role of this mutation in recombinant human UGT1A1 and UGT1A6
(mutant forms 1YD and 6YD, respectively). Control and mutant UGTs were expressed as
His-tagged proteins in baculovirus-infected insect cells. The Y486D mutation lowered the
normalised glucuronidation rate in UGT1A1 to 13 - 17% and in UGT1A6 to 4 - 6% of wild-
type, depending on the substrate used.
UGT1A4 is a human UGT that specialises in the glucuronidation of aglycones carrying
an amine group (Green and Tephly, 1998; Tukey and Strassburg, 2000). Its rate of
glucuronidation of phenolic compounds is very low and therefore HA-tagged UGT1A4 (HA-
1A4) was used as a “silent partner” in co-expression studies. The interactions between
UGT1A4 and the 6YD mutant increased the mutant activities remarkably: the normalised
scopoletin glucuronidation activity in cells co-infected with HA-1A4 and His-6YD was over
20 times higher than in cells infected with 6YD alone. The scopoletin activity of HA-1A4
with respect to 6YD was negligible, so the increase in activity must be a consequence of the
co-infection, not of intrinsic UGT1A4 activity. Co-expression of UGT1A4 with 1YD had a
minor effect on activity towards scopoletin compared to cells infected with 1YD alone,
possibly reflecting the tendency of UGT1A1 to form homo-oligomers (Ghosh, et al., 2001).
The single-point activity measurements were followed by kinetic analyses using 1-
naphthol as the aglycone. The Y485D mutation increased the Km for both the UDPGA and
the aglycone in recombinant UGT1A6. Surprisingly, the interaction of UGT1A4 with 6YD
changed both Km values in this mutant to values very close to the respective Km values  for
wild-type UGT1A6. In addition, I demonstrated by affinity chromatography using an IMAC
that  HA-1A4  and  His-6YD  isoforms  interact  with  each  other.  When  His-tagged  6YD  was
eluted from the column, HA-tagged UGT1A4, which normally would not bind to the
column, was present in the same fractions.
The activity increase by other UGTs was studied further: 6YD was co-expressed
individually with 14 different UGT isoforms and the serotonin glucuronidation activity was
measured, since serotonin is a rather selective UGT1A6 substrate (Court, 2005). All the
UGTs studied, except UGT2B28, stimulated serotonin glucuronidation, although the impact
of UGT1A5, UGT1A9 and UGT2B10 was quite small. Interestingly, even the 1YD and 4YD
mutants, which have the same mutation as 6YD in the carboxy-terminal domain, stimulated
serotonin glucuronidation when co-expessed with 6YD.
41
This study suggests that protein-protein interactions between individual UGT isoforms
influence glucuronidation activity. Those interactions may attenuate the consequences of the
Y486D mutation in all members of the UGT1 subfamily, though the study mostly focused on
UGT1A6. To ensure that the observed interactions were not caused by the His- or HA-tags,
we did co-infections with untagged UGTs. In these studies the co-infection either increased
or decreased the activity, suggesting that interactions between different isoforms might have
a regulatory role, controlling the enzyme activity in vivo as well. Other studies published
after  the  submission  of  our  manuscript  have  come to  similar  conclusions  (Fujiwara, et al.,
2007a; Fujiwara, et al., 2007b; Lévesque, et al., 2007).
5.2. UDPGA binding (Study II+III)
While seeking a suitable low activity mutant for the hetero-oligomerisation studies, we also
considered the H371A mutation, because it had been shown to decrease 4-MU activity
considerably and was believed to have a catalytic role in UGT1A6 (Ouzzine, et al., 2000).
We therefore made the equivalent mutation in UGT1A9. However, when the 9H369A
scopoletin glucuronidation activity was measured, the normalised activity appeared to be
about 40% of the wild type, which is very high if the residue has a role in catalysis. This
observation prompted us instead to study some other residues in this region of the enzyme.
E379 was the next residue examined. It seemed to be involved in co-substrate binding rather
than chemical catalysis. Thus, both Study II and Study III investigate a co-substrate binding
by site-directed mutagenesis, modelling and single-point activity and kinetic measurements.
5.2.1. Kinetic studies
The following residues, H371 and E379 in UGT1A6, H369 and E377 in UGT1A9, D393,
Q394, D396 and K399 in UGT1A10, and D398 and Q399 in UGT2B7 were mutated to
alanine, the corresponding mutants were produced, and their roles investigated by single-
point activity and kinetic measurements (Fig. 5.1).
UGT1A6  371: HAGSHGVYESICNGVPMVMMPLFGDQMDNAK : 401
UGT1A9  369: HAGSHGVYESICNGVPMVMMPLFGDQMDNAK : 399
UGT1A10 369: HAGSHGVYESICNGVPMVMMPLFGDQMDNAK : 399
UGT2B7  374: HGGANGIYEAIYHGIPMVGIPLFADQPDNIA : 404
Figure 5.1 Sequence alignment of the carboxy-terminal portion of UGT1A6, 1A9, 1A10 and 2B7
showing the residue numbering and the mutated residues. This part of the sequence is totally
identical in the UGT1A subfamily. The residues mutated to alanine in Study II and III are marked
with a grey background.
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5.2.1.1. 6H371A, 6E379A, 9H369A, 9E377A
In Study II I first examined residues H371 and E379 (UGT1A6 numbering) as potential
catalytic residues, but discovered that they are involved in UDPGA binding rather than
catalysis. UGT1A6 and UGT1A9 exhibited different responses to the mutations, even though
both mutations are in the identical carboxy-terminal domain (Fig. 5.1). The mutant activities
in UGT1A6 were low with all the measured substrates, but variable in UGT1A9.
Nonetheless, the kinetic studies revealed that the catalytic efficiency is severely impaired for
both mutants and in both UGTs studied, and the total impairment of the catalytic activity was
larger in UGT1A6, which is usually a highly active isoform (Table 5.1).
Table 5.1 Catalytic efficiencies of UGT1A6, UGT1A9 and their mutants. Vmax values are











UGT1A6 0.256 0.257 7.17 0.42
6H371A 0.0023 0.0076 0.036 0.0014
6E379A 0.0020 0.0083 0.11 0.0028
In the scopoletin kinetic assays at a constant UDPGA concentration, the Km values for
aglycone were very similar for 6H371A, 6E379A and 9H369A (1.5 – 1.7 mM) and, even
though an accurate Km could not be obtained for 9E377A, it was estimated to be about the
same (around 2 mM). The aglycone kinetic curves were quite similar for all the mutants (Fig.
5.2 A, D).
I measured the Km for UDPGA at a constant scopoletin concentration for all mutants
except for 9E377A, where the aglycone was not soluble at high enough concentrations. For
this mutant, I also could not detect the Km for UDPGA, because the velocity was far below
the Vmax even at 20 mM UDPGA (Fig. 5.2F). The co-substrate Km values varied from 3.9 to
7.6 mM when determined at a constant scopoletin concentration, but were lower when
determined by bisubstrate kinetics, where both substrate concentrations are varied. UGT1A9
seemed to have higher UDPGA Km values for both H and E mutants than UGT1A6 (Fig. 5.2
B, F). The dissociation constant value, Kd, determined by bisubstrate kinetics for the
UGT1A6 mutants, was nine times higher for 6H371A and 33 times higher for 6E379A than
for wild-type. This is the only study thus far where bisubstrate kinetics has been performed
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for UGT-mutant forms, and it clearly indicates that both H371 and E379 are involved in
UDPGA binding as both Km and Kd values are highly affected (see also section 5.4).
A. B.





































































































Figure 5.2 Kinetic curves of H A and E A mutants of both UGT1A6 and UGT1A9 isoforms. The
Km values for scopoletin (aglycone) are quite similar between the UGT1A6 and UGT1A9 mutants,
but the kinetic curves measuring UDPGA Km values differ noticeably from each other, showing that
the UDPGA Km is more affected in the UGT1A9 than in the UGT1A6 mutant.
5.2.1.2. 10D393, 10Q394, 10D396 and 10K399
In addition to H371 and E379 in UGT1A6, the D393 and Q394 residues in UGT1A10
and the equivalent residues, D398 and Q399, in UGT2B7 have been suggested to be
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involved in UDPGA binding. They are both highly conserved among GT1 enzymes. In the
solved GT1 structures, D or E with the subsequent Q is present in all except UrdGT2, which
has V and L instead (Mittler, et al., 2007) (Fig. 2.7). In the GT1 structures these residues
make contacts to the sugar moiety of the nucleotide donor. UrdGT2 is not highly selective
for the sugar donor: the main co-substrate is dNDP-D-olivose, but it can also accept dNDP-D-
mycarose (Trefzer, et al., 2002) or dNDP-rhodinose (Hoffmeister, et al., 2003). The structure
of the sugar moiety in some of these compounds does not allow the same interactions that
D/E and Q form in most other GT1 enzymes. The D/E equivalent E392 in UDP-
glucose:isoflavone 7-O-glucosyltransferase, GmIF7GT, has been suggested to play a
catalytic role in this enzyme (Noguchi, et al., 2007).
Surprisingly, mutating D393 and Q394 to alanine in UGT1A10 had different effects than
mutating the corresponding residues in UGT2B7. The 10D393A mutant had no measurable
activity with any of the five substrates studied, but the 10Q394A mutant had low to moderate
activity with all of them. Conversely, the 2B7D398A mutant had some activity with three of
the substrates studied, but 2B7Q399A was almost inactive. The activity measurements
showed the importance of these residues, but kinetic analysis using paranitrophenol as the
aglycone could be performed only on the D396 and K399 mutants; the other mutants were
too inactive.
Mutating D396 and K399 to alanine had only minor effects on activity. The catalytic
efficiency  was  not  much  affected,  and  all  the  other Km values  were  close  to  the  wild  type
value, except the paranitrophenol Km for K399A, which increased three-fold. These two
residues thus are not in direct contact with the substrates.
5.2.2. Modelling
The role of the mutated residues was further investigated by modelling studies. In both
Study II and III, I constructed a homology model of a part of the carboxy-terminal domain.
Due to the shared exons, the UGT1A6 (Study II) and UGT1A10 (Study III) carboxy-terminal
sequences are totally identical; the residue numbering differs because the amino-terminal
domains are not the same size (Fig. 5.1).
In Study II, the human UGT2B7 structure coordinates were not available and the most
similar available GT1 structures, the triterpene/flavonoid glucosyltransferase UGT71G1 from
the legume Medicago truncatula (PDB entries 2ACV and 2ACW) (Shao, et al., 2005) and
the UDP-glucose:flavonoid 3-O-glucosyltransferase from red grape (VvGT1) (PDB entries
2C1X, 2C1Z and 2C9Z) (Offen, et al., 2006) were used as templates. In Study III, the model
was based on the partial structure of human UGT2B7 (PDB entry 2O6L) (Miley, et al.,
2007). Due to the different templates, I obtained two dissimilar models of the carboxy-
terminal part of the human UGT1A subfamily. The RMSD difference between the models is
2.01 Å, but in the UDPGA–binding area, which was the main focus of these studies, it is
only 0.7 Å. The main dissimilarities between the models are in the loop regions, which are
flexible and so difficult to model. The positions of the -helices and -sheets and the main
contacts to the UDPGA co-substrate, are very similar in both models.
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My modelling in the carboxy-terminal region mainly focused on residues H371, E379,
D395 and Q396. The models constructed support the activity and kinetic data, suggesting
that these four residues make contacts to co-substrate. E379 makes hydrogen bonds to the
ribose ring in uridine, H371 to the phosphate group and D395 and Q396 to the glucuronic
acid moiety of UDPGA. All these residues and interactions are highly conserved among GT1
enzymes (Fig. 2.7). Residues 10D396 and 10K399 are not predicted to make any direct
contacts to UDPGA. Based on both models, they are 8 – 10 Å away from UDPGA and they
might rather interact with residues in the amino-terminal domain.
The two models predict some other contacts to the co-substrate. The main chain of L354
and the side chains of Q356 and R335 may hydrogen bond to the uridine group (Miley, et al.,
2007; Li and Wu, 2007; Locuson and Tracy, 2007). In both models these three residues
surround the UDPGA binding pocket (Fig. 5.5). In UGT1A1, mutation of R336 (R335 in
UGT1A6) to leucine, glutamine or tryptophan has been reported to cause the more severe
form of hyperbilirubinemia, CN-I (Servedio, et al., 2005).
Due to the different templates, the models also differ somewhat. One difference is W353,
which has been suggested to form ring stacking contacts to the uracil ring (Miley, et al.,
2007; Li and Wu, 2007; Locuson and Tracy, 2007). In the UGT1A6 model (Study II) and in
the plant proteins used as templates, this interaction exists (Shao, et al., 2005; Offen, et al.,
2006). However, in the UGT1A10 model based on human UGT2B7, W353 would have to
adopt a different rotamer conformation to be able to form -stacking interactions to the uracil
ring (Figs. 5.5 and 5.6). The structure of UGT2B7 does not have a bound co-substrate, and
residue W353 probably adopts a different conformation upon UDPGA binding. This is true
in UGT85H2, which also does not have a co-substrate bound (Shao, et al., 2005; Offen, et
al., 2006; Li, et al., 2007b). An equivalent tryptophan that makes ring stacking contacts to
the uracil is found in most of the GT1 structures and is missing only in bacterial GtfA, GtfB
and GtfD, which are close homologs involved in vancomycin synthesis (Figs. 2.7 and 5.3).
A second difference between the models is the position of S308. It is within hydrogen
bonding distance of UDPGA in the UGT1A6 model (Study II), but a little further away in
the UGT1A10 model (Study III). This serine residue and the preceding glycine are highly
conserved in GT1s (Fig. 5.4). They are usually located in the loop region, except in CalG3
from Micromonospora echinospora, where they are in the -helix (Zhang, et al., 2008). In
MurG, there were large changes in the corresponding “GGS” loop between the free and co-
substrate (UDP-N-acetylglucosamine)-bound enzyme structures (Hu, et al., 2003). In the
plant  UGT85H2  structure  without  bound  UDP-glucose,  the  loop  is  not  in  the  same
conformation as in VvGT1 and UGT71G1 with UDP-glucose bound (Shao, et al., 2005;
Offen, et al., 2006; Li, et al., 2007b). This might also be the case with human UGTs; the
loop may adopt different conformations with and without UDPGA. So far this serine has not
been mutated in any of the human UGTs, but mutating the equivalent residue to alanine in
the plant UGT71G1 led to a total loss of activity (He, et al., 2006) and mutation in the
preceding glycine (G308E in UGT1A1) has been reported to lead to CN-I in humans
(Labrune, et al., 1994). Miley et al. (2007) mutated S308 in UGT2B7, which is equivalent to
S305 in UGT1A6 and is not as conserved as the GS-motif (Fig. 5.4). The S308A mutation
had only a minor effect on enzyme activity (Miley, et al., 2007).
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Figure 5.3 Cladogram of 14 GT1 enzymes and one GT28 enzyme (MurG). It shows the relative
evolutionary distances between the proteins. The complete structures of all the enzymes are available
except the human UGTs. GtfA, GtfB, GtfD, MurG, UrdGT2, CalG3, OleI and OleD come from
bacteria (brown), and VvGT1, UGT85H2, UGT71G1 and UGT72B1 (green) come from plants.
UGT1A6, UGT1A10 and UGT2B7 (black) are human enzymes. The sequence alignment was made by
ClustalW (Larkin, et al., 2007) and the cladogram by Phylogenetic tree plot
(http://www.bioinformatics.nl/tools/plottree.html).
S305 S308
                            
UGT1A    : EAYINASGEHGIVVFSLGSMV : 310
UGT2B7   : EDFVQSSGENGVVVFSLGSMV : 313
UGT2B10  : EEFVQSSGENGVVVFSLGSMV : 312
GtfB     : ELAAFLDAGPPPVYLGFGSLG : 249
GtfA     : ELEAFLAAGSTPVYVGFGSSS : 232
GtfD     : ELEAFLAAGSPPVHIGFGSSS : 248
OleI_bac : GTWEGPGDGRPVLLIALGSAF : 266
OleD_bac : GGWQRPAGAEKVVLVSLGSAF : 243
UGT72B1  : LKWLDNQPLGSVLYVSFGSGG : 279
UGT71G1  : LKWLDEQPDKSVVFLCFGSMG : 287
UGT85H2  : LDWLESKEPGSVVYVNFGSTT : 306
VvGT1    : LQWLKERKPTSVVYISFGTVT : 282
CalG3    : GDRLPPVPARPEVAITMGTIE : 243
UrdGT2   : EPWMYTRDTRQRVLVTSGSRV : 208
Figure 5.4 Alignment of GT1 enzymes around GS/GT residues. The V/I/LxxxxGS/GT –motif is
highly conserved among glycosyltransferases. The serines are numbered according to UGT1A6.
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The third difference is that the side chain of S374 points in opposite directions in the two
models (Figs. 5.5, 5.6). It is hydrogen bonded to the glucuronic acid group in the UGT1A10
model, but not in the UGT1A6 model. This residue is not conserved among GT1 enzymes
and not even among UGTs (Fig. 2.7). The existence of this interaction and its possible effect
on the glucuronidation differences between UGT2B7 and UGT1A10 could be studied further
by mutational and kinetic analysis.
The predicted UDPGA binding site in the models of UGT1A6 and UGT1A10 seems to
be very similar to that seen in the UGT2B7 structure; only a few residues within hydrogen
bonding distance to the UDPGA are not identical. In addition to S374, which is alanine in
UGT2B7, the subsequent residue is also different; it is histidine in UGT1s and asparagine in
UGT2B7. This residue is somewhat conserved among the GT1 subfamily, being asparagine
in plant proteins UGT71G1, UGT85H2, UGT72B1 and VvGT1 (Fig. 2.7). The structures of
UGT71G1, UGT72B1 and VvGT1 show that it hydrogen bonds to the oxygen of the -
phosphate of UDP. The structure of UGT85H2 does not have a co-substrate bound. Histidine
can make the same contacts, but mutagenesis could be used to study whether changing these
residues significantly affects the kinetic parameters of human UGTs.
Figure 5.5 The UDPGA binding pocket of the human UGT1A6 model based on the UGT2B7
structure.
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Figure 5.6 A ball and stick representation of the model based on the plant enzymes, VvGT1 and
UGT71G. UGT1A6 residue numbering is used. The main differences between the two models in the
UDPGA binding pocket are at S308, W353 and S374.
5.3. Aglycone binding and catalytic mechanism (Study IV)
When it turned out from my previous study that H371 in UGT1A6 is involved in UDPGA
binding rather than playing a role as a catalytic base, we started to look for other candidate
residues. Many GT1 enzymes seem to utilise a serine-protease-like catalytic mechanism,
where histidine abstracts a proton from the aglycone hydroxyl for nucleophilic attack at the
C1 carbon of glucuronic acid in UDPGA (Shao, et al., 2005; Offen, et al., 2006; Li, et al.,
2007b; Bolam, et al., 2007; Zhang, et al., 2008). By sequence comparison to the other GT1
structures, H37 in UGT1A9 seemed to be a good candidate for a catalytic base, even though
the histidine in this position is not totally conserved among human UGTs and has earlier
been proposed to have a structural rather than a catalytic role (Ouzzine, et al., 2000; 2003).
The assisting aspartate in UGT1A9 could be either D143 or D148 since they both are highly
conserved. Thus, four different mutants, H37A, H37D, D143A and D148A, were generated
in UGT1A9 and their behaviour was investigated by performing single-point activity and
kinetic measurements.
 As  UGT1A4  and  UGT2B10  are  the  only  two  human  UGTs  that  lack  the  “catalytic”
histidine and are more specialised for N-glucuronidation (Green and Tephly, 1998;





























































Figure 5.7 Two main types of glucuronidation. Glucuronidation of phenolic compounds leads to the
formation of O-glucuronides, and glucuronidation of amine compounds to N-glucuronides.
As we hypothesised, mutating this histidine to alanine decreased the Vmax with  all  the
studied phenolic compounds that lead to the formation of O-glucuronides, but had only a
moderate effect on the glucuronidation of the amine compounds that give rise to N-
glucuronides (Fig. 5.7). The 9H37D mutation decreased the activity with both types of
aglycone more than the 9H37A mutation. The Km value for the 9H37A mutant with N-
aglycones was similar to that of wild type, but 11 times higher than wild type with the O-
aglycone, scopoletin. (Scopoletin was the only O-aglycone where the mutant had enough
residual activity for kinetic studies). A similar effect was observed with 9D148A, although
the activities for both the aspartate mutants were very low. The aglycone Km for the 9D148A
mutant changed for the O-aglycones, scopoletin and 4-methylumbelliferone, but not for the
N-aglycone, 4-aminobiphenyl. The activity of the 9D143A mutant was low or unmeasurable
with all the substrates studied and the aglycone Km values  were  similar  to  that  of  the  wild
type. We could not detect any changes in UDPGA Km values for any of the mutants studied.
My data clearly show that a different mechanism is used in N- than in O-glucuronidation.
H37 and D148 have different roles with phenolic and amine substrates. H37 is not very
important with amine compounds, but is essential with phenolic compounds (Fig. 5.9).
However, in contrast to other GT1 enzymes that lose their activity totally upon mutating the
catalytic histidine or aspartate (Shao, et al., 2005; Offen, et al., 2006; Li, et al., 2007b),
human UGTs retain some residual activity. Mutation of the equivalent histidine in UGT1A1
(H39D) has been reported to lead to the milder form of hyperbilirubinemia, CN-II (Maruo, et
al., 2006). My results are in agreement with studies on the bifunctional O- and N- plant
glucosyltransferase UGT72B1, where it was shown that the corresponding histidine is
needed for O- but not for N-glycosylation (Brazier-Hicks, et al., 2007). Kubota et al. (2007)
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have shown that this histidine has an important role in differentiating between phenolic and
amine compounds. However, in those studies kinetic data were not presented. In addition, Li
et al. (2007a) reported that the P40H mutation conferred phenolic acitivity on UGT1A4. I
studied the same mutation in UGT1A4 before their paper was published, and in my
preliminary measurements could not detect any marked increase in glucuronidation of
phenolic compounds (unpublished results).
My work did not clearly show which of the mutated aspartates, D143 or D148 of
UGT1A9, functions in the putative His-Asp dyad. The Vmax of both mutants was low and
clear differences between O- and N-glucuronidation could not be detected. However, D143A
in UGT1A9, unlike D148A, did not change the aglycone Km, which would be expected from
a residue that does not make any direct contacts to the aglycone. On the other hand, all the
other studies so far have suggested that D148 is the aspartate in the catalytic dyad (Miley, et
al., 2007; Li and Wu, 2007; Locuson and Tracy, 2007; Li, et al., 2007a). The alignment also
supports that view (Fig. 5.8). Li et al. (2007a) have also measured higher activity for the
9D143A mutant than we detected. In principle, the aspartate could influence the orientation
of the histidine and thus change the Km values as observed in the 9D148A mutant. This kind
of behaviour has been reported in Ribonuclease A (Schultz, et al., 1998).
Our  results  thus  show that  H37 is  the  catalytic  residue  in  UGT1A9 and  has  a  different
role in N- and O-glucuronidation. Based on kinetic data, D143 functions in the His-Asp
catalytic dyad; however other studies as well as the sequence alignment suggest that D148
fullfills this role. Clarification of the role of these aspartates will require further studies.
D143 D148
                      
UGT1A4   : HLNATSFDVVLTDPVNLCGAVLAKYLSIPAV : 170
UGT1A9   : YLKESSFDAVFLDPFDNCGLIVAKYFSLPSV : 166
UGT2B7   : KVQESRFDVIFADAIFPCSELLAELFNIPFV : 169
UGT2B10  : KLQESRFDIVFADAYLPCGELLAELFNIPFV : 168
UGT72B1  : ----RLPTALVVDLFGTDAFDVAVEFHVPPY : 135
UGT71G1  : ------VVGLVLDFFCVSMIDVGNEFGIPSY : 139
OleI_bac : AYADDRPDLIVYDIASWPAPVLGRKWDIPFV : 134
OleD_bac : AYADDIPDLVLHDITSYPARVLARRWGVPAV : 129
GtfB     : -EGCAAVVTTGLLAAAIGVRSVAEKLGIPYF : 121
GtfA     : -EGCDAVVTTGLLPAAVAVRSMAEKLGIPYR : 120
GtfD     : -EGCAAVVAVGDLAAATGVRSVAEKLGLPFF : 122
UGT85H2  : --NVPPVTCLVSDCCMSFTIQAAEEFELPNV : 143
VvGT1    : --G-RPVSCLVADAFIWFAADMAAEMGVAWL : 137
UrdGT2   : FSRAWRPDLIVGGTMSYVAPLLALHLGVP-- : 117
CalG3    : LVDDYRPDLVVYEQGATVGLLAADRAGVPAV : 155
Figure 5.8 Sequence alignment of four human UGTs and eleven GT1 enzymes showing the two




























Figure 5.9 The different catalytic mechanisms for O- and N-glucuronidation in UGT1A9. A.
Proposed catalytic mechanism for O-glucuronidation, and B. for N-glucuronidation.
5.4. Substrate binding order (Study II, III, IV)
Studies of the binding order of the substrates over the past 30-plus years have led to different
conclusions as discussed in section 2.3.6. My data imply that the UDPGA binds first, as
concluded previously by Luukkanen et al. (2005). Mutations in the carboxy-terminal domain
that affect the Km for UDPGA also affect the Km for the aglycone, but the reverse is not true
for the amino-terminal mutations, some of which affect only the aglycone Km (see sections
5.2 and 5.3). So far we have not found any mutations that change only the Km for UDPGA
but not for the aglycone; on the other hand we have found several mutations that affect the
aglycone Km, but not that for UDPGA (this work and unpublished results). In addition, three
types of GT1 structures are available: 1) those without any substrate bound, 2) those with
nucleotide or nucleotide sugar bound, and 3) those with the ternary complex; however, no
structures exist that contain only the aglycone bound (Mulichak, et al., 2001; Mulichak, et
al., 2003; Mulichak, et al., 2004; ; Shao, et al., 2005; Offen, et al., 2006; Bolam, et al., 2007;
Li, et al., 2007b; Brazier-Hicks, et al., 2007; Mittler, et al., 2007). This is only consistent
with a compulsory ordered bi-bi mechanism where UDPGA binds first.
In the GT-B superfamily, MurG has also been shown to follow a compulsory ordered bi-
bi mechanism in which the sugar donor binds first (Chen, et al., 2002) and in BGT, UDP-
glucose binding is reported to increase the affinity for DNA (Morera, et al., 2001; Lariviere
and Morera, 2004). The UDPGA binding in UGTs probably induces a conformational
change that facilitates aglycone binding, as observed in some other glycosyltransferases




In the absence of a crystallographic structure for any mammalian UGTs, other methods have
been used to obtain structural information on these enzymes. In my Ph.D. work I have
studied both the quaternary and the tertiary structures of UGTs, concentrating on hetero-
oligomerisation, substrate binding sites and on catalytic mechanism.
Co-infection studies revealed interactions between wild type UGTs and mutant forms,
thus confirming that UGTs function as dimers or higher oligomers. Interactions between
monomers were shown to have an important compensating role in some pathological
mutations by increasing the severely depressed activity. The interactions between wild type
UGT isoforms were shown to increase or decrease the activity, thus suggesting an important
regulatory role for hetero-oligomerisation.
I also studied the substrate binding site. My data show that H371, E379, D395 and Q396
are involved in UDPGA binding and that other residues may have a role in co-substrate
binding. The effects of these carboxy-terminal mutations depend on both substrate and UGT-
isoform and are variable even within the UGT1 subfamily, where the carboxy-terminal half
of the protein is totally identical. Our work also supports the compulsory ordered bi-bi
mechanism, with UDPGA binding first.
By comparing the UGT sequence to those of the solved GT1 structures, I identified
possible catalytic residues in human UGTs. Many other GT1 family members utilise a
catalytic mechanism, in which a His-Asp pair forms a catalytic dyad. This mechanism was
also suggested for human UGTs. The proposed catalytic base is H37 in UGT1A9 but,
interestingly, UGT1A4 and UGT2B10, which tend to catalyse N-glucuronidation more, have
proline and leucine instead of the histidine. I was able to obtain kinetic data with one O- and
two N-aglcyones and showed that H37 was crucial in O-glucuronidation, but not in N-
glucuronidation. I also showed that D148 in UGT1A9 had different roles in N- and in O-
glucuronidation. My results suggest different catalytic mechanisms for these two types of
reactions. The data imply that the catalytic dyad in UGT1A9 is D143-H37, but cannot clearly
differentiate between the two aspartates studied.
Human UGTs are very important detoxifying enzymes and the impairment of their
function as a consequence of polymorphism or mutation can lead to severe drug side effects.
It is thus essential to learn more about the possible interactions between UGT isoforms and
the physiological significance of these interactions. Studying the mutant or polymorphic
forms with several substrates gives valuable information and can help to choose the right
medication and prevent serious side effects. This will be more important in the future as
personalised medicine develops. It is also important to be aware of possible protein-protein
interactions between isoforms in vivo before drawing too many far-reaching conclusions
based on in vitro studies with recombinant isoforms.
To be able to predict if a drug candidate is a UGT-inhibitor which might cause unwanted
side effects, we need more structural information on different UGT-isoforms, and their
differential substrate binding. Screening costs would be reduced if unintended inhibitor
molecules could be eliminated in the early phases of drug discovery. In addition, potential
glucuronidation or bioactivation of the new drug candidates has to be carefully examined,
and the pharmaceutical industry could benefit from this structural information. This kind of
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knowledge is also needed when designing specific inhibitors. In particular, the observed
mechanistic difference between N- and O- glucuronidation opens up interesting possibilities
to devise specific mechanism-based inhibitors for different UGT-isoforms.
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